{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:23:04Z","timestamp":1773091384351,"version":"3.50.1"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study simulates a novel prostate SBRT intra-fraction re-optimization workflow in MRIgART to account for prostate intra-fraction motion and evaluates the dosimetric benefit of reducing PTV margins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>VMAT prostate SBRT treatment plans were created for 10 patients using two different PTV margins, one with a 5 mm margin except 3 mm posteriorly (standard) and another using uniform 2 mm margins (reduced). All plans were prescribed to 36.25 Gy in 5 fractions and adapted onto each daily MRI dataset. An intra-fraction adaptive workflow was simulated for the reduced margin group by synchronizing the radiation delivery with target position from cine MRI imaging. Intra-fraction delivered dose was reconstructed and prostate DVH metrics were evaluated under three conditions for the reduced margin plans: Without motion compensation (no-adapt), with a single adapt prior to treatment (ATP), and lastly for intra-fraction re-optimization during delivery (intra). Bladder and rectum DVH metrics were compared between the standard and reduced margin plans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As expected, rectum V18 Gy was reduced by 4.4 \u00b1 3.9%, D1cc was reduced by 12.2 \u00b1 6.8% (3.4 \u00b1 2.3 Gy), while bladder reductions were 7.8 \u00b1 5.6% for V18 Gy, and 9.6 \u00b1 7.3% (3.4 \u00b1 2.5 Gy) for D1cc for the reduced margin reference plans compared to the standard PTV margin. For the intrafraction replanning approach, average intra-fraction optimization times were 40.0 \u00b1 2.9 seconds, less than the time to deliver one of the four VMAT arcs (104.4 \u00b1 9.3 seconds) used for treatment delivery. When accounting for intra-fraction motion, prostate V36.25 Gy was on average 96.5 \u00b1 4.0%, 99.1 \u00b1 1.3%, and 99.6 \u00b1 0.4 for the non-adapt, ATP, and intra-adapt groups, respectively. The minimum dose received by the prostate was less than 95% of the prescription dose in 84%, 36%, and 10% of fractions, for the non-adapt, ATP, and intra-adapt groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intra-fraction re-optimization improves prostate coverage, specifically the minimum dose to the prostate, and enables PTV margin reduction and subsequent OAR sparing. Fast re-optimizations enable uninterrupted treatment delivery.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1325105","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:43:51Z","timestamp":1704692631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Simulating an intra-fraction adaptive workflow to enable PTV margin reduction in MRIgART volumetric modulated arc therapy for prostate SBRT"],"prefix":"10.3389","volume":"13","author":[{"given":"Jeffrey","family":"Snyder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel St.","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","unstructured":"Key Statistics for Prostate Cancer: American Cancer Society2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.03.024","article-title":"Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012","volume":"112","author":"Barton","year":"2014","journal-title":"Radiotherapy Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20789","article-title":"Estimating the optimal external-beam radiotherapy utilization rate for genitourinary Malignancies","volume":"103","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis primers."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat oncology biology physics."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14 168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncologica."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14798","article-title":"Rectal\/urinary toxicity after hypofractionated vs conventional radiotherapy in low\/intermediate risk localized prostate cancer: systematic review and meta analysis","volume":"8","author":"Di Franco","year":"2017","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0191-9","article-title":"Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis","volume":"23","author":"Malouff","year":"2020","journal-title":"Prostate Cancer prostatic diseases."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet (London England)."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Physics."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000548","article-title":"Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer","volume":"8","author":"Hodges","year":"2012","journal-title":"J Oncol Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1748-717X-8-171","article-title":"Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study","volume":"8","author":"Alongi","year":"2013","journal-title":"Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.2022.40.6_suppl.255","article-title":"Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial","volume":"40","author":"Kishan","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.10.072","article-title":"Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study","volume":"75","author":"Sandler","year":"2010","journal-title":"Urology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00116-6","article-title":"Quantification of organ motion during conformal radiotherapy of the prostate by three dimensional image registration","volume":"33","author":"van Herk","year":"1995","journal-title":"Int J Radiat OncologyBiologyPhysics."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.04.051","article-title":"Intrafractional motion of the prostate during hypofractionated radiotherapy","volume":"72","author":"Xie","year":"2008","journal-title":"Int J Radiat oncology biology physics."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40778","article-title":"Stereotactic body radiation therapy for prostate cancer using tomotherapy with synchrony fiducial tracking","volume":"15","author":"Shintani","year":"2023","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1120\/jacmp.v16i6.5691","article-title":"Determination of optimal PTV margin for patients receiving CBCT-guided prostate IMRT: comparative analysis based on CBCT dose calculation with four different margins","volume":"16","author":"Gill","year":"2015","journal-title":"J Appl Clin Med Phys"},{"key":"B24","doi-asserted-by":"publisher","first-page":"E748","DOI":"10.1016\/j.ijrobp.2019.06.862","article-title":"Dosimetric effects of intrafraction motion detected by triggered imaging during prostate SBRT","volume":"105","author":"Bright","year":"2019","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20160312","DOI":"10.1259\/bjr.20160312","article-title":"Target margins in radiotherapy of prostate cancer","volume":"89","author":"Yartsev","year":"2016","journal-title":"Br J Radiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14122","article-title":"Evaluation of Unity 1.5 T MR-linac plan quality in patients with prostate cancer","author":"Tanaka","year":"2023","journal-title":"J Appl Clin Med Phys"},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","article-title":"Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac","volume":"151","author":"de Muinck Keizer","year":"2020","journal-title":"Radiotherapy Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiotherapy Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2021.07.010","article-title":"On-line daily plan optimization combined with a virtual couch shift procedure to address intrafraction motion in prostate magnetic resonance guided radiotherapy","volume":"19","author":"de Muinck Keizer","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.06.004","article-title":"Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking","volume":"3","author":"Chaurasia","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejmp.2020.06.010","article-title":"Dosimetric effect of intrafraction motion and different localization strategies in prostate SBRT","volume":"75","author":"Vanhanen","year":"2020","journal-title":"Physica Medica."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-023-01304-w","article-title":"Dynamic intrafractional position monitoring with implanted fiducial markers for enhanced accuracy in radiotherapy of prostate cancer","volume":"46","author":"Mangesius","year":"2023","journal-title":"Phys Eng Sci Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-019-00760-7","article-title":"Assessment of the accuracy of truebeam intrafraction motion review (IMR) system for prostate treatment guidance","volume":"42","author":"Kaur","year":"2019","journal-title":"Australas Phys Eng Sci Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ab2ba8","article-title":"Real-time intrafraction motion monitoring in external beam radiotherapy","volume":"64","author":"Bertholet","year":"2019","journal-title":"Phys Med Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1088\/0031-9155\/61\/8\/R90","article-title":"Review of ultrasound image guidance in external beam radiotherapy part II: intra-fraction motion management and novel applications","volume":"61","author":"O\u2019Shea","year":"2016","journal-title":"Phys Med Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.04.013","article-title":"Prostate SBRT with intrafraction motion management using a novel linear accelerator\u2013based MV-kV imaging method","volume":"10","author":"Gorovets","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.04.014","article-title":"Triggered imaging with auto beam hold and pre-\/posttreatment CBCT during prostate SABR: analysis of time efficiency, target coverage, and normal volume changes","volume":"11","author":"Kisivan","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-02005-1","article-title":"Assessment of intrafractional prostate motion and its dosimetric impact in MRI-guided online adaptive radiotherapy with gating","volume":"199","author":"Xiong","year":"2023","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1098593","article-title":"Intra-fraction motion of pelvic oligometastases and feasibility of PTV margin reduction using MRI guided adaptive radiotherapy","volume":"13","author":"Snyder","year":"2023","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.05.008","article-title":"Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy","volume":"79","author":"Peng","year":"2011","journal-title":"Int J Radiat OncologyBiologyPhysics."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.03.013","article-title":"Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer","volume":"170","author":"Wahlstedt","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ac5299","article-title":"Reducing MRI-guided radiotherapy planning and delivery times via efficient leaf sequencing and segment shape optimization algorithms","volume":"67","author":"Snyder","year":"2022","journal-title":"Phys Med Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.3390\/jcm10153396","article-title":"Non-adaptive MR-guided radiotherapy for prostate SBRT: less time, equal results","volume":"10","author":"Sandoval","year":"2021","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13014-022-02047-w","article-title":"Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial","volume":"17","author":"Ristau","year":"2022","journal-title":"Radiat Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.04.022","article-title":"Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy","volume":"171","author":"Willigenburg","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2019.12.010","article-title":"Automatic reconstruction of the delivered dose of the day using MR-linac treatment log files and online MR imaging","volume":"145","author":"Menten","year":"2020","journal-title":"Radiotherapy Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"20200848","DOI":"10.1259\/bjr.20200848","article-title":"Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes","volume":"94","author":"Alongi","year":"2020","journal-title":"Br J Radiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13014-021-01916-0","article-title":"Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer","volume":"16","author":"Schaule","year":"2021","journal-title":"Radiat Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5\u2009T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.12902","article-title":"Commissioning of a 1.5T Elekta Unity MR-linac: A single institution experience","volume":"21","author":"Snyder","year":"2020","journal-title":"J Appl Clin Med Phys"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aa9517","article-title":"First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment","volume":"62","author":"Raaymakers","year":"2017","journal-title":"Phys Med Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.07.014","article-title":"Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac","volume":"162","author":"Muinck Keizer","year":"2021","journal-title":"Radiotherapy Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.07.004","article-title":"First experimental demonstration of VMAT combined with MLC tracking for single and multi fraction lung SBRT on an MR-linac","volume":"174","author":"Uijtewaal","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"04LT1","DOI":"10.1088\/1361-6560\/abd66d","article-title":"Proof-of-concept delivery of intensity modulated arc therapy on the Elekta Unity 1.5 T MR-linac","volume":"66","author":"Kontaxis","year":"2021","journal-title":"Phys Med Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e28111","DOI":"10.1097\/MD.0000000000028111","article-title":"SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review","volume":"100","author":"Payne","year":"2021","journal-title":"Medicine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/jcm11061662","article-title":"Clinical implementational and site-specific workflows for a 1.5T MR-linac","volume":"11","author":"Dunkerley","year":"2022","journal-title":"J Clin Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/mp.16342","article-title":"Real-time motion monitoring using orthogonal cine MRI during MR-guided adaptive radiation therapy for abdominal tumors on 1.5T MR-Linac","volume":"50","author":"Jassar","year":"2023","journal-title":"Med Phys"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/mp.14230","article-title":"Feasibility of real-time motion tracking using cine MRI during MR-guided radiation therapy for abdominal targets","volume":"47","author":"Keiper","year":"2020","journal-title":"Med Physics."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2019.04.001","article-title":"Adaptive radiotherapy: The Elekta Unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin Trans Radiat Oncol"},{"key":"B63","first-page":"1683","article-title":"Effects of varying statistical uncertainty using a Monte Carlo based treatment planning system for VMAT","volume":"26","author":"Rembish","year":"2021","journal-title":"J BUON"},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","article-title":"Errors and margins in radiotherapy","volume":"14","author":"van Herk","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2022.09.004","article-title":"Clinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion","volume":"176","author":"Willigenburg","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","article-title":"Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial","volume":"135","author":"Alayed","year":"2019","journal-title":"Radiotherapy Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13014-018-1112-0","article-title":"ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I\/II trial","volume":"13","author":"Zilli","year":"2018","journal-title":"Radiat Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.05.007","article-title":"Achievable dosimetric constraints in stereotactic reirradiation for recurrent prostate cancer","author":"Baty","year":"2023","journal-title":"Practical Radiation Oncology: An official journal of the American Society for Radiation Oncology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"109441","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiotherapy Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.tipsro.2022.08.005","article-title":"Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac","volume":"23","author":"Dang","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1325105\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:43:56Z","timestamp":1704692636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1325105\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":70,"alternative-id":["10.3389\/fonc.2023.1325105"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1325105","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1325105"}}